期刊
LIVER INTERNATIONAL
卷 43, 期 3, 页码 528-530出版社
WILEY
DOI: 10.1111/liv.15513
关键词
competing risk; immune checkpoint inhibitors; immunotherapy; liver cancer; overall survival; prognosis; progression; surrogacy; tyrosine kinase inhibitors